# Actinium Pharmaceuticals Shares Rise Following Cancer Treatment Data Presentations

- URL: https://stocks.freetheai.org/news/actinium-pharmaceuticals-shares-rise-following-cancer-treatment-data-e4f06b
- Published: 2026-10-19T14:11:59Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [AMEX:ATNM](https://stocks.freetheai.org/symbols/AMEX-ATNM)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Actinium Pharmaceuticals, Inc. (ATNM) saw its stock advance as the company highlighted clinical and preclinical data for ATNM-400 at the European Association of Nuclear Medicine annual congress in Vienna. Shares traded up 15.81% to $1.309 following the scientific presentations.

The presentations feature early results from an ongoing Phase 1 study evaluating ATNM-400 in metastatic castration-resistant prostate cancer, focusing on imaging, safety, and dosing guidance. Preclinical data also demonstrated activity in non-small cell lung cancer models both as a single therapy and in combination with other treatments. ATNM-400 is an investigational antibody radioconjugate targeting HER3 across solid tumors.

Market participants will watch for further clinical updates as the company develops the candidate to expand targeted radiotherapies across lung cancer subtypes and other solid tumors.

## Key points

- Actinium Pharmaceuticals shares increased 15.81% to $1.309 following data presentations on candidate ATNM-400.
- Clinical Phase 1 research covers ATNM-400 in metastatic castration-resistant prostate cancer, evaluating imaging and dosing.
- Preclinical studies showed ATNM-400 activity in KRAS- and ALK-driven non-small cell lung cancer models.
- ATNM-400 is an investigational HER3-targeting radioconjugate being tested for multiple solid tumor types.

## Questions and answers

### Why did Actinium Pharmaceuticals stock go up?

Actinium Pharmaceuticals shares rose after the company presented clinical and preclinical data for its investigational cancer drug ATNM-400 at a nuclear medicine conference.

### What is ATNM-400?

ATNM-400 is an investigational antibody radioconjugate targeting HER3, being developed to treat metastatic castration-resistant prostate cancer and non-small cell lung cancer.

### What data was presented for ATNM-400?

Presentations included early Phase 1 trial imaging, safety, and dosing results in prostate cancer, alongside preclinical results in lung cancer models as both a monotherapy and combination therapy.